<style face="normal" font="default" size="100%">TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">TRAIL modulates the immune system and protects against the development of diabetes.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Two‑gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">TRAIL, a new weapon against neointimal hyperplasia.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.</style>